Skip to content

Effects of Exogenous Relaxin on Dry Eye in an Experimental Sjögren's disease (SS) Mouse Model.

Oct 2026 · Experimental Eye Research · pp. 111280 · 0 citations · 54 references
Medicine

TL;DR

Exogenous relaxin shows therapeutic potential for DED in SS, demonstrated by clinical improvements and reduced inflammatory markers in an animal model of SS.

Abstract

Purpose

To evaluate the potential of exogenous relaxin (RLX) as a treatment for dry eye disease (DED) in an experimental animal model of Sjögren's disease (SS).

Methods

Nonobese diabetic female (NOD) mice with SS-associated DED received RLX-based or vehicle eye drops (100ng/mL) four times daily for 30 days. Clinical evaluations included measurements of tear production, assessment of keratitis, and histological analysis of the exorbital lacrimal gland. Inflammatory cytokine expression was measured using PCR.

Results

RLX-treated mice showed significant improvement in tear production and keratitis reversal. Qualitative histological analysis suggested better preservation of lacrimal gland architecture, with more evident acinar and ductal structures in the RLX-treated group. PCR analysis demonstrated reduced inflammatory cytokine expression (IL-1β, IL-6, IL-12a, IL-17a, TNFα, and IFNγ), and increased expression of RLX and its receptor RXFP1 in the RLX-treated group

Conclusions

Exogenous relaxin shows therapeutic potential for DED in SS, demonstrated by clinical improvements and reduced inflammatory markers in an animal model of SS.

View source

Similar papers

Open access Sep 2026

The effect of 0.1% topical ciclosporin a for 12-weeks on the ocular surface innate and adaptive immune response in dry eye disease: protocol for a randomized controlled clinical trial

Abstract Background Ocular surface immune cells and pro-inflammatory cytokines have been reported to be increased in Dry eye disease (DED). Immunosuppressive agents such as topical cyclosporine A (CsA) can inhibit dendritic cell and T cell activation. However, CsA’s impact on ocular surface immune responses and tear cy...

Soumen Sadhu, Isabelle Jalbert, Meng-Liang Wu et al. · 0 citations
Open access Sep 2026

Yiguanjian alleviates ocular surface inflammation and lacrimal gland immune dysregulation in experimental dry eye disease: evidence from in vivo and in vitro models

Background Persistent ocular surface inflammation and lacrimal gland immune dysregulation are central to the progression of dry eye disease (DED). Th17/Treg imbalance contributes to sustained inflammatory activation in the ocular surface and lacrimal gland. Yiguanjian (YGJ) has anti-inflammatory and immunomodulatory po...

Yuan Zhong, Jian Shi, Xi-Yuan Liu et al. · 0 citations
Open access Sep 2026

Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model

Allergic eye disease (AED), including allergic conjunctivitis, is a prevalent immune-mediated disorder of the ocular surface characterized by itching, redness, tearing, and ocular discomfort. Although olopatadine (OLO) is widely used as an antihistamine and mast cell stabilizer, its broader effects on immune-mediated i...

Basanta Bhujel, Kyu Sang Eah, Soon-Suk Kang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.